Theseus Pharmaceuticals, Inc. Quarterly Research and Development Expense in USD from Q3 2020 to Q3 2023

Taxonomy & unit
us-gaap: USD
Description
The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.
Summary
Theseus Pharmaceuticals, Inc. quarterly/annual Research and Development Expense history and growth rate from Q3 2020 to Q3 2023.
  • Theseus Pharmaceuticals, Inc. Research and Development Expense for the quarter ending September 30, 2023 was $11.5M, a 0.84% increase year-over-year.
  • Theseus Pharmaceuticals, Inc. Research and Development Expense for the twelve months ending September 30, 2023 was $47.2M, a 55.7% increase year-over-year.
  • Theseus Pharmaceuticals, Inc. annual Research and Development Expense for 2022 was $35.7M, a 94.8% increase from 2021.
  • Theseus Pharmaceuticals, Inc. annual Research and Development Expense for 2021 was $18.3M, a 208% increase from 2020.
Research and Development Expense, Trailing 12 Months (USD)
Research and Development Expense, Quarterly (USD)
Research and Development Expense, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2023 $47.2M $11.5M +$96K +0.84% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-17
Q2 2023 $47.1M $12.9M +$5.58M +75.9% Apr 1, 2023 Jun 30, 2023 10-Q 2023-08-10
Q1 2023 $41.6M $12.4M +$5.85M +89.4% Jan 1, 2023 Mar 31, 2023 10-Q 2023-05-11
Q4 2022 $35.7M $10.4M +$5.36M +107% Oct 1, 2022 Dec 31, 2022 10-K 2023-03-09
Q3 2022 $30.3M $11.4M +$6.43M +129% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-17
Q2 2022 $23.9M $7.34M +$2.86M +63.7% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-10
Q1 2022 $21.1M $6.55M +$2.72M +71.2% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-11
Q4 2021 $18.3M $5.02M Oct 1, 2021 Dec 31, 2021 10-K 2023-03-09
Q3 2021 $5M +$3.72M +292% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-03
Q2 2021 $4.49M Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-11
Q1 2021 $3.83M Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-12
Q3 2020 $1.28M Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-15
* An asterisk sign (*) next to the value indicates that the value is likely invalid.